- 全部删除
您的购物车当前为空
Ravoxertinib (GDC-0994) 是可口服的ERK 激酶抑制剂,抑制ERK1和ERK2的IC50分别为 6.1 和 3.1 nM。

Ravoxertinib (GDC-0994) 是可口服的ERK 激酶抑制剂,抑制ERK1和ERK2的IC50分别为 6.1 和 3.1 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 539 | In stock | |
| 2 mg | ¥ 792 | In stock | |
| 5 mg | ¥ 1,230 | In stock | |
| 10 mg | ¥ 1,970 | In stock | |
| 25 mg | ¥ 3,380 | In stock | |
| 50 mg | ¥ 3,980 | In stock | |
| 100 mg | ¥ 5,670 | In stock | |
| 200 mg | ¥ 7,680 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,180 | In stock |
Ravoxertinib 相关产品
| 产品描述 | Ravoxertinib (GDC-0994) is an effective and orally available ERK1/2 inhibitor (IC50: 1.1/0.3 nM). |
| 靶点活性 | p-RSK:12 nM, ERK1:1.1 nM, ERK2:0.3 nM |
| 体外活性 | GDC-0994对肿瘤细胞中的磷酸-p90RSK有显著抑制作用。 |
| 体内活性 | GDC-0994(p.o.)可抑制体内ERK磷酸化和ERK介导的信号转导通路的激活,随后阻碍ERK依赖性肿瘤细胞增殖和存活.在体外癌症模型中,GDC-0994(p.o.)可造成显著的多重单剂量活性,包括BRAF突变型和KRAS突变型人异种移植肿瘤的小鼠. |
| 别名 | GDC-0994 |
| 分子量 | 440.86 |
| 分子式 | C21H18ClFN6O2 |
| CAS No. | 1453848-26-4 |
| Smiles | Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |
| 密度 | 1.45 g/cm3 (Predicted) |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 81 mg/mL (183.73 mM), Sonication is recommended. DMSO: 81 mg/mL (183.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容